Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03513731 · ClinicalTrials.gov registry record · NA
Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint
A NA study of Osteoarthritis of Facet Joint of Lumbar Spine, sponsored by InGeneron.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT03513731 is a NA study of Osteoarthritis of Facet Joint of Lumbar Spine that is actively recruiting participants, run by InGeneron. The registered enrollment target is 40 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03513731, a NA study of Osteoarthritis of Facet Joint of Lumbar Spine, is actively recruiting participants, sponsored by InGeneron.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective, randomized, active controlled, single site safety and efficacy study in subjects suffering from chronic lumber back pain due to facet joint osteoarthritis comparing a single ADRC injection generated with the Transpose® RT system into the facet joint.
Conditions Studied
Interventions
- DRUG Corticosteroid injection
- DEVICE Adipose-derived stem cell injection
Study Locations (2)
Florida
- Sports and Orthopedic Center - Deerfield Beach
South Dakota
- Sanford Physical Medicine & Rehabilitation Clinic and Sanford Spine Center - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2026-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03513731
The ClinicalTrials.gov registry entry for NCT03513731 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InGeneron, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis of Facet Joint of Lumbar Spine appearing as the primary indexed condition, and to 2 interventions - of which Corticosteroid injection is the first listed.
NCT03513731 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, South Dakota.
Frequently Asked Questions
What is clinical trial NCT03513731 about?
NCT03513731 is a clinical study titled "Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint". This is a prospective, randomized, active controlled, single site safety and efficacy study in subjects suffering from chronic lumber back pain due to facet joint osteoarthritis comparing a single ADRC injection generated with the Transpose® RT system into the facet joint.
What is the current status of trial NCT03513731?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2018-12-07. Estimated completion is 2026-04.
What conditions does trial NCT03513731 study?
This clinical trial studies the following conditions: Osteoarthritis of Facet Joint of Lumbar Spine.
What interventions are being tested in trial NCT03513731?
The interventions under investigation include: Corticosteroid injection (DRUG), Adipose-derived stem cell injection (DEVICE).
Who is sponsoring clinical trial NCT03513731?
This trial is sponsored by InGeneron, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03513731 being conducted?
This trial has 2 study locations across Florida, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.